Effect of serotypes on clinical manifestations of dengue fever in adults.

BACKGROUND AND PURPOSE Dengue fever (DF) is a major public health issue. However, it is unclear whether different dengue virus serotypes (DENV) are associated with different clinical manifestations and outcomes. This study investigated the association between viral serotype and clinical manifestations of DF. METHODS Adult patients with DENV-2 and DENV-3 who were treated at Kaohsiung Medical University Hospital and Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan, from January 1998 to September 2007 were enrolled. The patients' demographic data, underlying diseases, clinical manifestations, laboratory data, and disease outcomes were retrospectively analyzed. RESULTS 294 patients had DENV-2 and 91 had DENV-3. The median age was 50 years, and 45.7% of patients were men. Patients with DENV-3 were more likely to have a malignancy (p = 0.011), myalgia (p = 0.03), skin rash (p < 0.001), ascites (p = 0.04), and fever (p = 0.003) than patients with DENV-2. Patients with DENV-3 had their lowest levels of white blood cells and platelets, and peak plasma activated partial thromboplastin time (aPTT) 1 day later than patients with DENV-2. DENV-2 infection was associated with a higher monocyte count and more prolonged aPTT early in the clinical course. Infection by DENV-2 more commonly occurred as a secondary infection, while infection by DENV-3 was more common as a primary infection (p < 0.001). There were no differences between the groups in organ involvement, disease severity, duration of hospital stay, and medical expenditure. CONCLUSION The symptoms, signs, and laboratory findings appear to be different for patients infected with DENV-2 and DENV-3, but there is no difference in outcomes.

[1]  R. He,et al.  Antibody-enhanced binding of dengue-2 virus to human platelets. , 1995, Virology.

[2]  P. Glaziou,et al.  Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. , 1994, The Journal of infectious diseases.

[3]  S. Halstead Is there an inapparent dengue explosion? , 1999, The Lancet.

[4]  M. Tsai,et al.  Immunomodulatory mast cells: negative, as well as positive, regulators of immunity , 2008, Nature Reviews Immunology.

[5]  Ko Yc Epidemiology of dengue fever in Taiwan , 1989 .

[6]  A. Nisalak,et al.  A prospective study of dengue infections in Bangkok. , 1988, The American journal of tropical medicine and hygiene.

[7]  S. Halstead,et al.  Epidemiologic studies on Dengue in Santiago de Cuba, 1997. , 2000, American journal of epidemiology.

[8]  A. Nisalak,et al.  Dengue in the early febrile phase: viremia and antibody responses. , 1997, The Journal of infectious diseases.

[9]  Ting-Hsiang Lin,et al.  Comparison of Capture Immunoglobulin M (IgM) and IgG Enzyme-Linked Immunosorbent Assay (ELISA) and Nonstructural Protein NS1 Serotype-Specific IgG ELISA for Differentiation of Primary and Secondary Dengue Virus Infections , 2003, Clinical Diagnostic Laboratory Immunology.

[10]  L. Rosen,et al.  Recovery of virus from the liver of children with fatal dengue: reflections on the pathogenesis of the disease and its possible analogy with that of yellow fever. , 1989, Research in virology.

[11]  W. J. McBride,et al.  Dengue viral infections; pathogenesis and epidemiology. , 2000, Microbes and infection.

[12]  J. Schlesinger,et al.  Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells , 2008, Journal of medical virology.

[13]  S. Kalayanarooj,et al.  Clinical and Laboratory Presentations of Dengue Patients with Different Serotypes , 2000 .

[14]  M. Guzmán,et al.  Description of the clinical picture of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) in adults. , 1988, Bulletin of the Pan American Health Organization.

[15]  Yee‐Shin Lin,et al.  Generation of IgM anti‐platelet autoantibody in dengue patients , 2001, Journal of medical virology.

[16]  P. Shu,et al.  Laboratory-based dengue surveillance in Taiwan, 2005: a molecular epidemiologic study. , 2007, The American journal of tropical medicine and hygiene.

[17]  M. Guzmán Deciphering Dengue: The Cuban Experience , 2005, Science.

[18]  M. Guzmán,et al.  Dengue: an update. , 2002, The Lancet. Infectious diseases.

[19]  Halstead Sb,et al.  Dengue: hematologic aspects. , 1982 .

[20]  Y. Ko [Epidemiology of dengue fever in Taiwan]. , 1989, Gaoxiong yi xue ke xue za zhi = The Kaohsiung journal of medical sciences.

[21]  Robert Anderson,et al.  Dengue Virus Selectively Induces Human Mast Cell Chemokine Production , 2002, Journal of Virology.

[22]  J. Stephenson Understanding dengue pathogenesis: implications for vaccine design. , 2005, Bulletin of the World Health Organization.

[23]  Tyen‐Po Chen,et al.  Clinical characteristics of dengue and dengue hemorrhagic fever in a medical center of southern Taiwan during the 2002 epidemic. , 2006, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[24]  M. Guzmán,et al.  Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). , 1987, Bulletin of the Pan American Health Organization.

[25]  Chung-Te Chang,et al.  Status of Dengue Control Programme in Taiwan − 2001 , 2002 .

[26]  M. Shaio,et al.  Production of cytokines and platelet activating factor in secondary dengue virus infections. , 1995, The Journal of infectious diseases.